Drug intelligence / Profile preview

Juvéderm Volite

Development stage: Unknown
Lead developer: AbbVie
Administration: Intradermal

Overview

Juvéderm Volite is a resorbable, injectable medical device (dermal filler) composed of cross-linked hyaluronic acid (12 mg/mL) and 0.3% lidocaine hydrochloride. Developed by Allergan using Vycross™ technology, it is designed to improve skin quality attributes such as hydration and elasticity and to treat superficial skin depressions like fine lines. The product is administered via intradermal injection and is indicated for use in the face, neck, décolletage, and hands, with clinical effects lasting between 6 to 9 months.

Brand names: Juvéderm Volite
Other names: VYC-12LVYC12LVYC 12L

Beyond the preview

Go deeper on Juvéderm Volite.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juvéderm Volite.

Explore the full profile